Valued at US$ 3.86 billion in 2022, the market for unstable angina therapeutics is foreseen to increase to US$ 4.05 billion in FY 2023, representing a Y-o-Y increase of 4.9%. Over the forecast period ranging from 2023 to 2033, the market is anticipated to gain traction at a CAGR of 5%, reaching an industry value of US$ 6.6 billion. According to a Cleveland Clinic report, approximately 200,000 Americans suffer from unstable angina every year. Unstable angina is more prevalent among older people, men, and those who smoke, have high blood sugar levels, or have hypertension.
The primary factors driving the market growth are an augmentation in the number of patients being treated for unstable angina and the authorization of new therapeutics with high safety and effectiveness. Rivaroxaban, varespladib, and otamixaban are a few instances of new therapeutics that are presently in the late phases of clinical progression. If authorized, these products are predicted to be advertised at high prices. Nevertheless, a low adoption rate of therapeutic strategies in a generics-dominated industry would slow the expansion of the unstable angina therapeutics market.
If there is an artery obstruction or shrinking, the practitioner may suggest invasive surgery like angioplasty, and in severe instances, cardiac bypass surgery. The market for unstable angina therapeutics has tremendous growth potential, owing primarily to a rise in the number of people suffering from cardiac ailments, increased tobacco use, poor dietary habits, and lifestyle changes. Therefore, increasing awareness about lifestyle changes is also predicted to boost market growth.
As per one 2020 article, roughly 18 million individuals in the United States suffer from unstable angina. Furthermore, the Americas are expected to represent the majority of global percutaneous coronary interventions. As percutaneous coronary intervention (PCI) is growing more prevalent in the United States and Canada, that region is expected to be the leader in the unstable angina therapeutics industry in the forthcoming years. Because of the increasing prevalence of cardiovascular diseases, enhanced medical facilities, and increasing disposable income, Asia-Pacific is estimated to accelerate at the fastest pace. The Middle East and Africa market share are predicted to grow due to the significant recurrence of therapeutic intervention in Kuwait, Saudi Arabia, and the UAE.
Aspects such as the soaring prevalence of numerous cardiovascular disorders including Coronary Heart Disease (CHD), myocardial infarction, and strokes, in addition to the growing requirement for minimally invasive surgeries, are contributing to the expansion of the coronary artery bypass graft (CABG) surgery segment. Nonsteroidal anti-inflammatory drugs (NSAIDs) are growing in popularity due to variables such as the growing incidence of pain around the world, as well as an enhancement in the worldwide aging populations. Because of the high adoption rate of effective therapies for unstable angina patients, the hospital segment held the largest market share among end-user segments.
Leading healthcare practitioners in the market are employing a variety of therapeutic and combat strategies. These include a variety of measures such as pipeline research to develop effective drug applicants, in-house therapy sessions, and collaboration with healthcare technology providers to establish advanced therapeutics infrastructures.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | US$ 4.05 billion |
| Anticipated Forecast Value (2033) | US$ 6.6 billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to Future Market Insights, unstable angina therapeutics experienced a substantial boost from 2018 to 2022, with a CAGR of 4%. COVID-19 had become a significant public health concern in the historical period. In the past, unsuitable cautions against the usage of NSAID stimulants for COVID-19 patients with a higher likelihood of adverse impacts have been imposed. This caused widespread consternation among patient populations and the healthcare sector. As a result, COVID-19 had a significant impact on the consumption and prescription of various drugs for unstable angina in the global market.
Increasing medical prices will raise the economic strain on uninsured patients over the projected timeframe, causing individuals to migrate to developing countries where surgery costs less. This, in turn, is increasing the need for medical tourism in evolving countries. Among the main determinants predicted to propel the market in emerging economies over the forecast period are the presence of advantages like improved healthcare, lower surgical costs, and superior hospitality.
Global Geriatric Population Growth to steer Market Growth
As a result, the growing elderly population around the world is predicted to propel market growth. Based on an Administration on Aging (AoA) report, the number of people aged 65 and older in the United States was about 54.1 million in 2019, accounting for more than 16% of the total population.
There were approximately 30 million women and approximately 24.1 million men among them. By 2040, this population is predicted to account for 21.6% of the total in the United States. As a result, the growing geriatric population is predicted to drive the expansion of the unstable angina therapeutics market in the coming years.
Drugs Authorization by government drives Market Growth
The increasing number of medications approved by government agencies is expected to drive the growth of the unstable angina therapeutics market in the coming decades. Clopidogrel, for instance, is FDA-approved for the medical treatment of unstable angina (UA)/non-ST-segment elevation myocardial infarction (NSTEMI).
Clopidogrel, when combined with aspirin, has historically been demonstrated to lower the probability of death, reoccurring heart attacks, or stroke in patient populations with unstable angina or a less severe cardiac attack.
Principal Consultant
Low Adoption Rate of Treatment and High Costs to Hinder Market Growth
Nevertheless, a low adoption rate of new treatments in a generics-dominated industry would slow the expansion of the unstable angina therapeutics market. Other attributes like patent expirations and the exorbitant prices of drug development may also impede market growth. For instance, a coronary artery bypass graft surgery costs an average of $54,000 - $148,400 in the United States.
Advanced Surgeries and Treatments Options drive the Regional Market Growth
Owing to the evolving guidelines related to patient treatment and management, North America is anticipated to dominate the unstable angina therapeutics market over the coming years. The occurrence of unstable angina is escalating in the United States, with nearly 1 million hospitalized patients having a primary diagnosis of unstable angina every year. As a result, this aspect is anticipated to contribute to industry growth.
Furthermore, North America is predicted to control the whole coronary artery bypass graft surgery market across the forthcoming years, driving future growth even further. For instance, as per data released by the Centers for Disease Control and Prevention in July 2022, 20.1 million Americans aged 20 and adults over the age were impacted by coronary heart disease in 2020. North America accounted for 45% market share in 2022.
Europe is the world's 2nd largest market for Unstable Angina Therapeutics
According to a recent article in Academic Group, Europe is the second largest industry for unstable angina therapeutics. Aspects including the accessibility of research grants, a burgeoning obese and patient citizenry, and the involvement of advanced economies like France, Italy, and Germany in the region all provide favorable backdrops for regional market expansion.
Unstable angina causes over 115,000 acute hospitalizations in the UK each year (200 per 100,000 population), with a substantial male predominance. In Europe, hospitalization rates for unstable angina outnumber those for ST-elevation myocardial infarction1. Before the introduction of modern treatment modalities, 15% of patients with unstable angina proceeded to a severe myocardial infarction, with total in-hospital mortality reaching 5%. Thus these factors are expected to propel the regional market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Hospital Segment is Estimated to Hold the Largest Share
The hospital segment led the market in 2022, accounting for 46% of total revenue. Hospitals are commonly considered primary healthcare systems, and the patient population's preference for hospitals for the evaluation and treatment of chronic disorders is fuelling segment growth. Furthermore, the same segment is expected to grow at the fastest rate between 2023 and 2033.
Beta Blockers Segment is Estimated to Hold the Largest Share
The beta blockers segment is anticipated to expand at a CAGR of 4.4% during the projected timeline. Because of technological developments, massive expenditure, higher incidence and occurrence of cardiovascular diseases, and an aging population, the popularity of beta blockers has risen exponentially. Furthermore, the segment will benefit from a rising patient population and a lack of adequate treatment.
Various start-ups are launching advanced treatment procedures and drugs to drive market growth. For instance,
Key players in the Unstable Angina Therapeutics market are Bayer Healthcare, Sanofi, Anthera Pharmaceuticals, Ablynx, Saphnix Life Sciences, Copperhead Chemical, Medtronic, Enomark Kinetics, CDH Fine Chemical. Some of the latest developments are below,
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 4.05 billion |
| Anticipated Forecast Value (2033) | US$ 6.6 billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The global market size to reach US$ 6.6 million by 2033.
Bayer AG and Kinetics are the top key players.
The growth potential of the enterprise key management market is 5% through 2033
The low adoption of treatment rates is likely to limit market growth.
The hospital segment is highly preferred in the global market.
1. Executive Summary | Unstable Angina Therapeutics Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033
5.3.1. Percutaneous Coronary Intervention (PCI)
5.3.2. Coronary Artery Bypass Graft Surgery
5.3.3. Supplemental Oxygen Therapy
5.3.4. Drug Class
5.3.4.1. NSAIDs
5.3.4.2. Vasodilators
5.3.4.3. Platelet Aggregation Inhibitors
5.3.4.4. Anticoagulants
5.3.4.5. Beta-blockers
5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
6.3.1. Hospitals
6.3.2. Specialty Clinics
6.3.3. Ambulatory Surgical Centres
6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. United States
8.2.1.2. Canada
8.2.2. By Treatment
8.2.3. By End User
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Treatment
8.3.3. By End User
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Treatment
9.2.3. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Treatment
9.3.3. By End User
9.4. Key Takeaways
10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Europe
10.2.2. By Treatment
10.2.3. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Treatment
10.3.3. By End User
10.4. Key Takeaways
11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. China
11.2.1.2. Japan
11.2.1.3. South Korea
11.2.1.4. Singapore
11.2.1.5. Thailand
11.2.1.6. Indonesia
11.2.1.7. Australia
11.2.1.8. New Zealand
11.2.1.9. Rest of Asia Pacific
11.2.2. By Treatment
11.2.3. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Treatment
11.3.3. By End User
11.4. Key Takeaways
12. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. GCC Countries
12.2.1.2. South Africa
12.2.1.3. Israel
12.2.1.4. Rest of Middle East and Africa
12.2.2. By Treatment
12.2.3. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Treatment
12.3.3. By End User
12.4. Key Takeaways
13. Key Countries Market Analysis
13.1. United States
13.1.1. Pricing Analysis
13.1.2. Market Share Analysis, 2022
13.1.2.1. By Treatment
13.1.2.2. By End User
13.2. Canada
13.2.1. Pricing Analysis
13.2.2. Market Share Analysis, 2022
13.2.2.1. By Treatment
13.2.2.2. By End User
13.3. Brazil
13.3.1. Pricing Analysis
13.3.2. Market Share Analysis, 2022
13.3.2.1. By Treatment
13.3.2.2. By End User
13.4. Mexico
13.4.1. Pricing Analysis
13.4.2. Market Share Analysis, 2022
13.4.2.1. By Treatment
13.4.2.2. By End User
13.5. Germany
13.5.1. Pricing Analysis
13.5.2. Market Share Analysis, 2022
13.5.2.1. By Treatment
13.5.2.2. By End User
13.6. United Kingdom
13.6.1. Pricing Analysis
13.6.2. Market Share Analysis, 2022
13.6.2.1. By Treatment
13.6.2.2. By End User
13.7. France
13.7.1. Pricing Analysis
13.7.2. Market Share Analysis, 2022
13.7.2.1. By Treatment
13.7.2.2. By End User
13.8. Spain
13.8.1. Pricing Analysis
13.8.2. Market Share Analysis, 2022
13.8.2.1. By Treatment
13.8.2.2. By End User
13.9. Italy
13.9.1. Pricing Analysis
13.9.2. Market Share Analysis, 2022
13.9.2.1. By Treatment
13.9.2.2. By End User
13.10. China
13.10.1. Pricing Analysis
13.10.2. Market Share Analysis, 2022
13.10.2.1. By Treatment
13.10.2.2. By End User
13.11. Japan
13.11.1. Pricing Analysis
13.11.2. Market Share Analysis, 2022
13.11.2.1. By Treatment
13.11.2.2. By End User
13.12. South Korea
13.12.1. Pricing Analysis
13.12.2. Market Share Analysis, 2022
13.12.2.1. By Treatment
13.12.2.2. By End User
13.13. Singapore
13.13.1. Pricing Analysis
13.13.2. Market Share Analysis, 2022
13.13.2.1. By Treatment
13.13.2.2. By End User
13.14. Thailand
13.14.1. Pricing Analysis
13.14.2. Market Share Analysis, 2022
13.14.2.1. By Treatment
13.14.2.2. By End User
13.15. Indonesia
13.15.1. Pricing Analysis
13.15.2. Market Share Analysis, 2022
13.15.2.1. By Treatment
13.15.2.2. By End User
13.16. Australia
13.16.1. Pricing Analysis
13.16.2. Market Share Analysis, 2022
13.16.2.1. By Treatment
13.16.2.2. By End User
13.17. New Zealand
13.17.1. Pricing Analysis
13.17.2. Market Share Analysis, 2022
13.17.2.1. By Treatment
13.17.2.2. By End User
13.18. GCC Countries
13.18.1. Pricing Analysis
13.18.2. Market Share Analysis, 2022
13.18.2.1. By Treatment
13.18.2.2. By End User
13.19. South Africa
13.19.1. Pricing Analysis
13.19.2. Market Share Analysis, 2022
13.19.2.1. By Treatment
13.19.2.2. By End User
13.20. Israel
13.20.1. Pricing Analysis
13.20.2. Market Share Analysis, 2022
13.20.2.1. By Treatment
13.20.2.2. By End User
14. Market Structure Analysis
14.1. Competition Dashboard
14.2. Competition Benchmarking
14.3. Market Share Analysis of Top Players
14.3.1. By Regional
14.3.2. By Treatment
14.3.3. By End User
15. Competition Analysis
15.1. Competition Deep Dive
15.1.1. Bayer AG
15.1.1.1. Overview
15.1.1.2. Product Portfolio
15.1.1.3. Profitability by Market Segments
15.1.1.4. Sales Footprint
15.1.1.5. Strategy Overview
15.1.1.5.1. Marketing Strategy
15.1.2. Sanofi S.A
15.1.2.1. Overview
15.1.2.2. Product Portfolio
15.1.2.3. Profitability by Market Segments
15.1.2.4. Sales Footprint
15.1.2.5. Strategy Overview
15.1.2.5.1. Marketing Strategy
15.1.3. Anthera Pharmaceuticals Inc.
15.1.3.1. Overview
15.1.3.2. Product Portfolio
15.1.3.3. Profitability by Market Segments
15.1.3.4. Sales Footprint
15.1.3.5. Strategy Overview
15.1.3.5.1. Marketing Strategy
15.1.4. Ablynx
15.1.4.1. Overview
15.1.4.2. Product Portfolio
15.1.4.3. Profitability by Market Segments
15.1.4.4. Sales Footprint
15.1.4.5. Strategy Overview
15.1.4.5.1. Marketing Strategy
15.1.5. Saphnix Lifesciences
15.1.5.1. Overview
15.1.5.2. Product Portfolio
15.1.5.3. Profitability by Market Segments
15.1.5.4. Sales Footprint
15.1.5.5. Strategy Overview
15.1.5.5.1. Marketing Strategy
15.1.6. Copperhead Chemical Company
15.1.6.1. Overview
15.1.6.2. Product Portfolio
15.1.6.3. Profitability by Market Segments
15.1.6.4. Sales Footprint
15.1.6.5. Strategy Overview
15.1.6.5.1. Marketing Strategy
15.1.7. Medtronic Plc.
15.1.7.1. Overview
15.1.7.2. Product Portfolio
15.1.7.3. Profitability by Market Segments
15.1.7.4. Sales Footprint
15.1.7.5. Strategy Overview
15.1.7.5.1. Marketing Strategy
15.1.8. Enomark
15.1.8.1. Overview
15.1.8.2. Product Portfolio
15.1.8.3. Profitability by Market Segments
15.1.8.4. Sales Footprint
15.1.8.5. Strategy Overview
15.1.8.5.1. Marketing Strategy
15.1.9. Cytokinetics Inc.
15.1.9.1. Overview
15.1.9.2. Product Portfolio
15.1.9.3. Profitability by Market Segments
15.1.9.4. Sales Footprint
15.1.9.5. Strategy Overview
15.1.9.5.1. Marketing Strategy
15.1.10. CDH Fine Chemical
15.1.10.1. Overview
15.1.10.2. Product Portfolio
15.1.10.3. Profitability by Market Segments
15.1.10.4. Sales Footprint
15.1.10.5. Strategy Overview
15.1.10.5.1. Marketing Strategy
16. Assumptions & Acronyms Used
17. Research Methodology
Explore Healthcare Insights
View Reports
Unstable Angina Therapeutics Market
